News Anti-LINGO-1: All You Need to Know Anti-LINGO-1: All You Need to Know by admin | January 19, 2016 Share this article: Share article via email Copy article link Recently, Biogen released results from its Phase 2 acute optic neuritis (AON) RENEW trial which tested Anti-LINGO-1. Learn more about this results here. So what isĀ Anti-LINGO-1? According to the MS Society,Ā Anti-LINGO-1 (also known as BIIB033) is a treatment in development by the pharmaceutical company Biogen which is currently being tested in people with optic neuritis, relapsing-remitting MS, and secondary progressive MS. LINGO is a protein found in nerve cells and myelin-making cells called oligodendrocytes. Blocking the activity of this protein with an antibody called anti-LINGO-1 has been shown to result in myelin repair in animal models of MS. Anti-LINGO-1 itās taken as an intravenous infusion. Read the Anti-LINGO-1 latest news here:Ā https://bit.ly/1ZJzxrV Print This Page Tags ANTI-LINGO-1, Biogen, MS Society, optic neuritis, relapsing-remitting MS, RRMS, secondary progressive MS, SPMS
March 28, 2024 News by Marisa Wexler, MS Smartphone, wearable device data found reliable to monitor MS: Study
March 28, 2024 Columns by Benjamin Hofmeister Multiple sclerosis awareness is for people with MS, too
March 28, 2024 News by Lindsey Shapiro, PhD Restoring ‘lost’ pathway of neuroprotection benefits MS mice